DDR1 and multiple sclerosis: Pagan et al. (2019) also found that nilotinib increases the cerebrospinal fluid (CSF) levels of TREM2 and potentially reduces oligomeric alpha-synuclein in human PD patients. Mo et al. (2019) looked for causal associations of sites and genes in multiple sclerosis (MS) and found multiple SNPs, DNA methylation sites, and differential gene expression for DDR1. They also identified an MS-associated methylation site near AGPAT1, another DMR identified in the present work (Mo et al., 2019).